The Scientist - Home

A lack of funding for the country’s main research agency threatens the future of Brazilian scientific research.

Oxytetracycline, approved by the US government to combat citrus scourge, may not work—at least not as a spray.

Broken links, clunky formats, and outdated platforms have both authors and publishers turning to alternative solutions.

Scientists spent five years reconstructing what is now the oldest HIV-1 genome yet recovered.

The company Cell Vault offers to hold consumers’ T cells for later use, but scientists suggest the service would benefit very few users.

The glia seem to make up part of a newly described sensory organ, the discoverers suggest.

Physical activity, independent of diet, shifts the composition of bacteria in the intestines, spurring researchers to search for species that might provide benefits akin to working out.

Stop Animal Exploitation Now issues a federal complaint against Johns Hopkins scientists, saying they messed up surgeries on nine animals.

The US Food and Drug Administration green lights a therapy for an extreme form of multidrug resistant TB.

Novartis, which bought the biotech firm in 2018, announced that the company’s top scientists have left, and news reports say it’s because they were involved in using manipulated data to get the gene therapy Zolgensma approved.

The results of an early trial in 31 brain cancer patients finds immune activity boosted in the tumor, and possibly longer survival.

In Niger, fewer kids die when health workers administer azithromycin routinely, perhaps because of a shift in the composition of gut microbes.